Ultramicronized palmitoylethanolamide (Um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): Retrospective observational study on 407 patients
(2019)
fibromyalgia syndrome is a chronic multifaceted disease characterized by widespread pain, muscle stiffness, fatigue, unrefreshing sleep and cognitive disorders. To date, no medication has been shown to significantly improve pain, associated symptoms and Quality of Life in fibromyalgic patients.
Product ID:
109340
Handle IRIS:
11562/997490
Last Modified:
February 17, 2024
Bibliographic citation:
Schweiger, V; Martini, A; Bellamoli, Paola; Donadello, K; Schievano, C; Del Balzo, G; Sarzi-Puttini, P; Parolini, M; Polati, E,
Ultramicronized palmitoylethanolamide (Um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): Retrospective observational study on 407 patients«CNS & NEUROLOGICAL DISORDERS. DRUG TARGETS»
, vol. 18
, n. 4
, 2019
, pp. 326-333